Newbury Pharmaceuticals AB (publ) reported earnings results for the fourth quarter ended August 31, 2023. For the fourth quarter, the company reported sales was SEK 2.83 million compared to SEK 4.57 million a year ago. Net loss was SEK 4.75 million compared to SEK 3.9 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.22 SEK | -3.01% |
|
-6.94% | +4.89% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.89% | 7.37M | |
-12.65% | 7.93B | |
+33.84% | 1.3B | |
-9.90% | 346M | |
+6.86% | 278M | |
+9.44% | 222M | |
-34.86% | 62.09M | |
+26.51% | 60.97M |
- Stock Market
- Equities
- NEWBRY Stock
- News Newbury Pharmaceuticals AB
- Newbury Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023